首页> 外文期刊>European journal of pharmaceutical sciences >A novel in vivo predictive dissolution testing coupled with a modeling and simulation for hydrogel matrix monolithic extended release oral dosage forms
【24h】

A novel in vivo predictive dissolution testing coupled with a modeling and simulation for hydrogel matrix monolithic extended release oral dosage forms

机译:一种新型的体内预测溶解试验,其与水凝胶基质整体延长释放口腔剂型的建模和模拟

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this research was to design a novel in vitro dissolution testing for hydrogel matrix monolithic extended release tablets, in which physiologically relevant conditions of swelling, stress, and erosion for the tablets in the fasted gastrointestinal tract are taken into consideration. Mirabegron extended release tablets ( three variations) were used as model formulations in this research. In in vitro dissolution testing, the tablets were allowed to swell in 10 mL of dissolution medium, after which they were stressed under a pressure of ca. 300 g/cm(2) and then allowed to erode in a very limited volume of intestinal fluid. The drug release results from this in vitro test were coupled with in silico modeling and simulation to predict individual plasma concentration profiles after oral administration of the extended release tablets to beagle dogs. The results of the in silico simulations indicated that the proposed approach is able to predict in vivo performance of the hydrogel matrix monolithic extended release tablets in individualized simulations.
机译:本研究的目的是为水凝胶基质单片延长释放片剂设计一种新的体外溶解试验,其中考虑了禁食胃肠道中的片剂的生理相关的肿胀,应力和腐蚀条件。 M拉释延长释放片剂(三种变异)用作本研究中的模型配方。在体外溶解试验中,将片剂溶于10mL溶解介质中,之后将它们在CA的压力下施压。 300g / cm(2),然后使其侵蚀非常有限的肠液。该体外测试的药物释放结果与硅建模和模拟相结合,以预测口服延长释放片剂的单独血浆浓度分布到Beagle犬。在硅模拟中的结果表明,该方法能够在个性化模拟中预测水凝胶基质整体延长释放片的体内性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号